Are Peptides Legal in Mississippi? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Mississippi as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Mississippi attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Mississippi statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Mississippi has scheduled or banned on its own. The Mississippi Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Mississippi's licensing boards have also spoken to peptide prescribing by clinics and medspas, which is where state-level risk actually sits (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Mississippi at a glance

State controlled-substances law: Miss. Code Ann. § 41-29-101 et seq. (Uniform Controlled Substances Law); Schedule III at § 41-29-117 (codes.findlaw.com)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Miss. Code Ann. § 41-29-117 (Schedule III)) (codes.findlaw.com)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy's compounding memo (April 2023, emailed to all medical licensees) states that semaglutide base is in an FDA-approved product but semaglutide sodium, semaglutide acetate and other salt forms are not, that the FDA had stated compounding with semaglutide salts does not meet the 503A bulk substance requirement, and that compounding in this manner may result in enforcement action by the FDA or the Board. It also warns that invoiced bulk substances may be research grade rather than pharmaceutical grade (2023-04) (mbp.ms.gov)
Medical board on peptide prescribing: A joint statement of the State Board of Medical Licensure, the Board of Nursing and the Board of Pharmacy (19 August 2026) says that under no circumstances may a healthcare provider compound, administer, dispense, advise, recommend, supply or prescribe a non-FDA-approved or research-grade peptide to a patient; that providers must buy all prescription products and ingredients from an entity permitted by the Board of Pharmacy; that consent forms labelling a product research-grade do not reduce liability; and that where a patient independently acquires and self-administers such substances the risk rests solely with the patient, while any professional involvement is the practice of medicine and prohibited. Earlier guidance (August 2023) told licensees to stop prescribing compounded semaglutide, and a 2024 order created a limited waiver for compounded GLP-1s only for a documented clinical need or during a shortage, with certificate-of-analysis and ingredient verification required (2026-08-19) (msbml.ms.gov)
GLP-1 by telehealth: Yes for a non-controlled GLP-1, with conditions. Medical board rules (Title 30, Part 2635, Rules 5.4 and 5.5) require a valid physician-patient relationship with an appropriate history and examination; the exam need not be in person if the technology is sufficient, and a simple questionnaire without an appropriate exam violates the policy and may bring discipline. The 30-day in-person re-evaluation rule applies only when controlled substances are used for weight loss. (msbml.ms.gov)
State-level enforcement, 2023 to 2026: 4 actions found
Last verified: 28 September 2026, confidence high

The federal rules that apply in Mississippi, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Mississippi:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Mississippi. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Mississippi law adds

Mississippi's controlled-substances law (Miss. Code Ann. § 41-29-101 et seq. (Uniform Controlled Substances Law); Schedule III at § 41-29-117) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Mississippi's schedules or in a Mississippi-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Mississippi's Schedule III lists 65 named anabolic steroids but not human growth hormone, somatropin or chorionic gonadotropin, so only the federal HGH statute applies. (Miss. Code Ann. § 41-29-117 (Schedule III)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

2023-04. The Board of Pharmacy's compounding memo (April 2023, emailed to all medical licensees) states that semaglutide base is in an FDA-approved product but semaglutide sodium, semaglutide acetate and other salt forms are not, that the FDA had stated compounding with semaglutide salts does not meet the 503A bulk substance requirement, and that compounding in this manner may result in enforcement action by the FDA or the Board. It also warns that invoiced bulk substances may be research grade rather than pharmaceutical grade. (mbp.ms.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

2026-08-19. A joint statement of the State Board of Medical Licensure, the Board of Nursing and the Board of Pharmacy (19 August 2026) says that under no circumstances may a healthcare provider compound, administer, dispense, advise, recommend, supply or prescribe a non-FDA-approved or research-grade peptide to a patient; that providers must buy all prescription products and ingredients from an entity permitted by the Board of Pharmacy; that consent forms labelling a product research-grade do not reduce liability; and that where a patient independently acquires and self-administers such substances the risk rests solely with the patient, while any professional involvement is the practice of medicine and prohibited. Earlier guidance (August 2023) told licensees to stop prescribing compounded semaglutide, and a 2024 order created a limited waiver for compounded GLP-1s only for a documented clinical need or during a shortage, with certificate-of-analysis and ingredient verification required. (msbml.ms.gov)

Buying, possessing and using research peptides in Mississippi

Miss. Code Ann. § 41-29-139(c) criminalises knowing possession of a controlled substance without a valid prescription; unscheduled research peptides are outside it, and the boards' 2026 statement expressly says a patient who independently acquires and self-administers such substances bears the risk alone, while any licensed provider's involvement is prohibited. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Mississippi is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes for a non-controlled GLP-1, with conditions. Medical board rules (Title 30, Part 2635, Rules 5.4 and 5.5) require a valid physician-patient relationship with an appropriate history and examination; the exam need not be in person if the technology is sufficient, and a simple questionnaire without an appropriate exam violates the policy and may bring discipline. The 30-day in-person re-evaluation rule applies only when controlled substances are used for weight loss. (msbml.ms.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Mississippi law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Mississippi

2023-05-18. The State Board of Medical Licensure suspended a physician's licence for three months for prescribing Ozempic through an instant-messaging telehealth platform with a questionnaire in place of an examination. (goodwinlaw.com)
2025-02-19. Mississippi's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)
2025-05-06. Attorney General Lynn Fitch issued a consumer alert warning about unapproved and compounded semaglutide and tirzepatide sold by compounders, medspas, online retailers and social media sellers. An alert, not a lawsuit. (wtok.com)
2026-08-19. The medical, nursing and pharmacy boards jointly barred all licensed providers from compounding, administering, dispensing, prescribing or recommending research-grade peptides, and told licensees to report unlicensed entities shipping prescription products into the state. (msbml.ms.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. Mississippi is the clearest state position on research peptides in the country: the boards do not restrict the buyer but prohibit every form of professional involvement. The medical board also bars off-label hCG solely for weight loss under Rule 1.5(F).

Frequently asked questions

Is BPC-157 legal in Mississippi?

Mississippi has not scheduled BPC-157, so possessing it is not a Mississippi offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Mississippi?

Yes for a non-controlled GLP-1, with conditions. Medical board rules (Title 30, Part 2635, Rules 5.4 and 5.5) require a valid physician-patient relationship with an appropriate history and examination; the exam need not be in person if the technology is sufficient, and a simple questionnaire without an appropriate exam violates the policy and may bring discipline. The 30-day in-person re-evaluation rule applies only when controlled substances are used for weight loss. The Mississippi Board of Pharmacy position on compounded versions: The Board of Pharmacy's compounding memo (April 2023, emailed to all medical licensees) states that semaglutide base is in an FDA-approved product but semaglutide sodium, semaglutide acetate and other salt forms are not, that the FDA had stated compounding with semaglutide salts does not meet the 503A bulk substance requirement, and that compounding in this manner may result in enforcement action by the FDA or the Board. It also warns that invoiced bulk substances may be research grade rather than pharmaceutical grade.

Is HGH legal in Mississippi?

Only with a valid prescription for an approved use. Mississippi does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Mississippi fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.